{"id":"NCT00424398","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis","officialTitle":"A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-02","primaryCompletion":"2007-07","completion":null,"firstPosted":"2007-01-19","resultsPosted":"2012-03-26","lastUpdate":"2013-02-15"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Conjunctivitis, Allergic"],"interventions":[{"type":"DRUG","name":"Bepreve","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Bepotastine Besilate","otherNames":[]}],"arms":[{"label":"Bepreve","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Bepotastine Besilate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis","primaryOutcome":{"measure":"Ocular Itching","timeFrame":"15 minutes, 8 hours & 16 hours post-dose from Conjunctival Allergen Challenge (CAC) Model","effectByArm":[{"arm":"Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%","deltaMin":0.5,"sd":0.8},{"arm":"Placebo","deltaMin":1.9,"sd":0.8},{"arm":"Bepotastine Besilate Ophthalmic Solution 1.0%","deltaMin":0.6,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22991696","20642205","19843481"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Mild Taste","Eye Irritation","Nasopharyngitis"]}}